-
Increase in Blood Glucose Concentration During Antihypertensive
Treatment as a Predictor of Myocardial Infarction; Adverse Drug Events
in Ambulatory Care; Prevention of Hip Fracture by External Hip
Protectors; Rapid MRI vs Radiographs for Patients with Low Back Pain;
Effectiveness of Anticholinergic Drugs Compared with Placebo in the
Treatment of Overactive Bladder; A Randomized Trial of a Low
Carbohydrate Diet for Obesity
-
Nasally Administered Flu Vaccine Comes to United States; Paxil: Not
Recommended for Children; Prilosec Granted OTC Status; Finasteride and
Prostate Cancer; Xolair: First Biologic Agent for Asthma; West Nile
Virus Update; Study Shows COX-2 Inhibitors Appear Safe with Aspirin in
Asthma Patients; Lamictal Approved for Bipolar Disorder
-
If you have any patients who use 28-day packages of Nortrel 7/7/7 oral contraceptives (OCs), be sure your clinic has initiated its patient notification plan following the July 9, 2003, voluntary recall issued by the pills manufacturer, Barr Laboratories of Pomona, NY.
-
The word is getting out about emergency contraception (EC). A just-released national survey reports that two-thirds of women ages 18-44 are aware that there is something a woman can do to prevent pregnancy in the few days following sexual intercourse.
-
Findings from a new Australian study indicate that use of modern, low-dose oral contraceptives (OCs) containing 50 mcg estrogen or less do not appear to appreciably raise the risk of ischemic stroke in healthy women.
-
Just-published papers in the Journal of the American Medical Association add to heightened concern regarding hormone therapy (HT).
-
The next patient in your exam room is a 32-year-old woman with type 2 (adult onset) diabetes. While she is obese, she does not smoke, and her chart shows no evidence of hypertension, nephropathy, or retinopathy. What birth control options can you offer her?
-
New video reviews teen birth control options; NAMS issues revised menopause guidelines
-
The Platelia Aspergillus EIA for detecting Aspergillus galactomannan in blood has been recently approved by the Food and Drug Administration for use in the United States.
-
Pyrazinamide was the most frequent cause of drug-related adverse events, especially hepatitis, among patients with tuberculosis receiving first-line drugs.
